CA
CHRS icon

CoreCap Advisors’s Coherus Oncology CHRS Stock Holding History

CoreCap Advisors’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Sell
2,435
-37
-1% -$60 ﹤0.01% 2386
2026
Q1 		$4.18K Buy
+2,472
New +$4.39K ﹤0.01% 2228

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

CoreCap Advisors's CHRS Position: Q2 2026 in Review

CoreCap Advisors reduced its Coherus Oncology (CHRS) stake by 1.5% in Q2 2026, selling an estimated $60 and leaving 2,435 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #2386.

CoreCap Advisors first reported a position in CHRS in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.18K in Q1 2026. 147 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • CoreCap Advisors held 2,435 shares of Coherus Oncology worth $3.41K as of Q2 2026.
  • CoreCap Advisors sold 37 Coherus Oncology shares in Q2 2026, an estimated $60.
  • Coherus Oncology made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2386 holding.
  • CoreCap Advisors first reported a position in Coherus Oncology in Q1 2026 and has held it in 2 quarters since.
  • CoreCap Advisors's Coherus Oncology position peaked at $4.18K in Q1 2026.
  • 147 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.